Results 11 to 20 of about 13,407 (237)

Ivabradine toxicity: a case report

Journal of Medical Case Reports, 2022
Background We describe a case of symptomatic bradycardia resulting from ivabradine toxicity by measurement of ivabradine levels, of which there are limited reports in the literature.
Kavisha Singh, Muthukumar R. Alagarraju, Carl E. Wolf, Justin L. Poklis, Nitin Kulkarni, William Tharpe, Parag H. Joshi   +6 more
doaj   +1 more source

Case report: Ivabradine induced Torsades de Pointes

IHJ Cardiovascular Case Reports, 2023
Ivabradine is used to control heart rate in patients of heart failure with reduced ejection fraction. Although considered safe, it is reported to prolong QTc interval when given with other QTc prolonging drugs or in setting of hypokalemia or ...
Mohit M. Bhagwati, K.K. Talwar, Amitabh Yaduvanshi   +2 more
doaj   +1 more source

Observational study of new-onset atrial fibrillation in patients treated with Ivabradine alone versus Ivabradine and β-blocker drug (The BetaBrad Study)

MGM Journal of Medical Sciences, 2022
Introduction: Ivabradine is a heart rate lowering agent by inhibiting Iƒ current in sinus node. It is approved for use in patients with angina and heart failure for heart rate control.
Rohan S Thanedar, Srinivas Kudva, Prakash Sanzgiri, Charan Reddy   +3 more
doaj   +1 more source

Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation

ESC Heart Failure, 2022
Aims Ivabradine is indicated for heart failure (HF) patients with reduced ejection fraction (HFrEF), but limited data are available with regards to the use of ivabradine in those with a history of paroxysmal atrial fibrillation (AF). To assess the effect
Yu‐Sheng Lin, Jeng‐Yu Jan, Jung‐Jung Chang, Ming‐Shyan Lin, Teng‐Yao Yang, Po‐Chang Wang, Mien‐Cheng Chen   +6 more
doaj   +1 more source

The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels

Frontiers in Pharmacology, 2022
Background and purpose: Ivabradine is clinically administered to lower the heart rate, proposedly by inhibiting hyperpolarization-activated cyclic nucleotide-gated cation channels in the sinoatrial node. Recent evidence suggests that voltage-gated sodium
Benjamin Hackl, Peter Lukacs, Janine Ebner, Krisztina Pesti, Krisztina Pesti, Nicholas Haechl, Mátyás C Földi, Mátyás C Földi, Elena Lilliu, Klaus Schicker, Helmut Kubista, Anna Stary-Weinzinger, Karlheinz Hilber, Arpad Mike, Arpad Mike, Hannes Todt, Xaver Koenig   +16 more
doaj   +1 more source

Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. [PDF]

PLoS ONE, 2012
BACKGROUND: Elevated heart rate is associated with increased cardiovascular morbidity. The selective I(f) current inhibitor ivabradine reduces heart rate without affecting cardiac contractility, and has been shown to be cardioprotective in the failing ...
Li Yue-Chun, Zhang Teng, Zhou Na-Dan, Ge Li-Sha, Luo Qin, Guan Xue-Qiang, Lin Jia-Feng   +6 more
doaj   +1 more source

Effects of selective heart rate reduction with ivabradine on LV function and central hemodynamics in patients with chronic coronary syndrome

International Journal of Cardiology: Heart & Vasculature, 2021
Objectives: We assessed left ventricular (LV) function and central hemodynamic effects in patients with a heart rate (HR) at rest of ≥70 beats per minute (bpm) and chronic coronary syndrome (CCS) after long-term treatment with ivabradine compared to ...
Anna Lena Hohneck, Peter Fries, Jonas Stroeder, Günther Schneider, Stephan Henrik Schirmer, Jan-Christian Reil, Michael Böhm, Ulrich Laufs, Florian Custodis   +8 more
doaj   +1 more source

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction

ESC Heart Failure, 2021
Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medications.
Ying‐Hsiang Lee, Po‐Lin Lin, Wei‐Ru Chiou, Jin‐Long Huang, Wen‐Yu Lin, Chia‐Te Liao, Fa‐Po Chung, Huai‐Wen Liang, Chien‐Yi Hsu, Hung‐Yu Chang   +9 more
doaj   +1 more source

Quality of life with ivabradine in patients with angina pectoris [PDF]

, 2016
Background—To explore the effect of ivabradine on angina-related quality of life (QoL) in patients participating in the Study Assessing the Morbidity–Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery Disease (SIGNIFY) QoL
Chassany, Olivier, Ferrari, Roberto, Ford, Ian, Fox, Kim, Steg, Philippe Gabriel, Tardif, Jean-Claude, Tendera, Michal   +6 more
core   +1 more source

Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study

Cardiology and Therapy, 2020
Introduction Dosing frequency is an important factor influencing medication compliance in patients with heart failure (HF), which in turn is imperative in achieving the desired therapeutic outcome.
Ajit Mullasari, The PROFICIENT investigators   +1 more
doaj   +1 more source